In this Review:
Duvelisib active in relapsed/refractory CLL
Ibrutinib + bendamustine/rituximab in previously treated CLL/SLL
MRD after chemoimmunotherapy induction for CLL predicts outcome
Physical examination and MRD better than CT to assess response to fludarabine chemoimmunotherapy
Bleeding-related AEs in ibrutinib-treated CLL
Atrial fibrillation and ibrutinib: advocacy for guidelines
A novel valid marker for discerning Richter’s syndrome
Lenalidomide + rituximab as initial treatment of CLL
Primary care management of early CLL is safe and effective
Please login below to download this issue (PDF)